Show simple item record

dc.contributor.authorHendrie, Delia
dc.contributor.authorMiller, T.
dc.contributor.authorWoodman, R.
dc.contributor.authorHoti, Kreshnik
dc.contributor.authorHughes, Jeffrey David
dc.date.accessioned2017-01-30T13:25:29Z
dc.date.available2017-01-30T13:25:29Z
dc.date.created2014-11-03T20:00:25Z
dc.date.issued2014
dc.identifier.citationHendrie, D. and Miller, T. and Woodman, R. and Hoti, K. and Hughes, J.D. 2014. Cost-Effectiveness of Reducing Glycaemic Episodes Through Community Pharmacy Management of Patients with Type 2 Diabetes Mellitus. The Journal of Primary Prevention. 35 (6): pp. 439-449.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/31443
dc.identifier.doi10.1007/s10935-014-0368-x
dc.description.abstract

Accessibility, availability and frequent public contact place community pharmacists in an ideal position to provide medically necessary, intensive health education and preventive health services to diabetes patients, thus reducing physician burden. We assessed the cost-effectiveness of reducing glycaemic episodes in patients with type 2 diabetes mellitus through a pharmacist-led Diabetes Management Education Program (DMEP) compared to standard care. We recruited eight metropolitan community pharmacies in Perth, Western Australia for the study. We paired them based on geographical location and the socioeconomic status of the population served, and then randomly selected one pharmacy in each pair to be in the intervention group, with the other assigned to the control group. We conducted an incremental cost-effectiveness analysis to compare the costs and effectiveness of DMEP with standard pharmacy care. Cost per patient of implementing DMEP was AU$394 (US$356) for the 6-month intervention period. Significantly greater reductions in number of hyperglycaemic and hypoglycaemic episodes occurred in the intervention relative to the control group [OR 0.34 (95 % CI 0.22, 0.52), p = 0.001; OR 0.54 (95 % CI 0.34, 0.86), p = 0.009], respectively, with a net reduction of 1.86 days with glycaemic episodes per patient per month. The cost-effectiveness of DMEP relative to standard pharmacy care was AU$43 (US$39) per day of glycaemic symptoms avoided. Patients with type 2 diabetes in three surveys were willing to pay an average of 1.9 times that amount to avoid a hypoglycaemic day. We conclude that DMEP decreased days with glycaemic symptoms at a reasonable cost. If a larger-scale replication study confirms these findings, widespread adoption of this approach would improve diabetes health without burdening general practitioners.

dc.publisherSpringer
dc.subjectBlock-randomised
dc.subjectIncremental cost-effectiveness ratio
dc.subjectIndicated prevention
dc.subjectHealth education
dc.subjectSF36
dc.titleCost-Effectiveness of Reducing Glycaemic Episodes Through Community Pharmacy Management of Patients with Type 2 Diabetes Mellitus
dc.typeJournal Article
dcterms.source.volume35
dcterms.source.startPage439
dcterms.source.endPage449
dcterms.source.issn0278-095X
dcterms.source.titleThe Journal of Primary Prevention
curtin.departmentCentre for Population Health
curtin.accessStatusFulltext not available


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record